National Bank of Canada FI Takes $60,000 Position in enVVeno Medical Corporation (NASDAQ:NVNO)

National Bank of Canada FI bought a new stake in shares of enVVeno Medical Corporation (NASDAQ:NVNO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 20,000 shares of the company’s stock, valued at approximately $60,000. National Bank of Canada FI owned about 0.11% of enVVeno Medical as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Westside Investment Management Inc. lifted its stake in enVVeno Medical by 132.0% in the fourth quarter. Westside Investment Management Inc. now owns 205,025 shares of the company’s stock worth $619,000 after purchasing an additional 116,650 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of enVVeno Medical in the fourth quarter worth approximately $39,000. Geode Capital Management LLC lifted its stake in shares of enVVeno Medical by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock worth $506,000 after acquiring an additional 10,902 shares during the last quarter. Virtu Financial LLC purchased a new position in enVVeno Medical during the 4th quarter valued at $86,000. Finally, Fermata Advisors LLC grew its position in enVVeno Medical by 18.1% in the 4th quarter. Fermata Advisors LLC now owns 35,706 shares of the company’s stock valued at $108,000 after acquiring an additional 5,481 shares during the last quarter. Hedge funds and other institutional investors own 34.71% of the company’s stock.

enVVeno Medical Trading Up 3.3 %

NASDAQ:NVNO opened at $2.19 on Friday. The company has a market cap of $38.40 million, a price-to-earnings ratio of -1.70 and a beta of 1.04. enVVeno Medical Corporation has a twelve month low of $2.03 and a twelve month high of $6.48. The stock has a fifty day simple moving average of $2.95 and a 200-day simple moving average of $3.13.

enVVeno Medical (NASDAQ:NVNO) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.05. As a group, equities research analysts predict that enVVeno Medical Corporation will post -1.32 EPS for the current fiscal year.

enVVeno Medical Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).